INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
GC
Corporate insider

Glessner Coleen

EVP, Quality & Ethics, and CPLCIK 0001919170

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 0
Max Insider Score23
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$16K
2,018 sh
Jun 8, 2026Jun 10, 2026
traded Jun 8, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Emergent BioSolutions Inc.EVP, Quality & Ethics, and CPL · Feb 10, 2026
21
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Grant or award
A
—
100.1K sh
Apr 29, 2026
May 1, 2026
traded Apr 29, 2026
+2d
SEC FORM 4

Evidence

16
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$69K
8,199 sh
Mar 5, 2026Mar 5, 2026
traded Mar 5, 2026
+0dSEC FORM 4

Evidence

13
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Grant or award
A—
44.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

23
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Disposition to issuer
D$315K
28.8K sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

9
GC
Glessner ColeenEVP, Quality & Ethics, and CPL
EBSEmergent BioSolutions Inc.
Tax withholding
F$31K
2,852 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

Data sources
SEC FORM 46m ago
HOUSE PTR6m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago